Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Raxflame is a combination analgesic and antipyretic medication marketed by Rax Health Care, primarily available as an oral suspension. It contains two active pharmaceutical ingredients: mefenamic acid and paracetamol (acetaminophen). Mefenamic acid is a non-steroidal anti-inflammatory drug (NSAID) belonging to the anthranilic acid derivatives class, which works by inhibiting the cyclooxygenase enzymes (COX-1 and COX-2), thereby reducing the production of inflammatory prostaglandins. Paracetamol serves as an additional analgesic and antipyretic agent, acting predominantly on the central nervous system to elevate the pain threshold and reduce fever. Raxflame is typically indicated for the symptomatic relief of mild to moderate pain and fever, particularly in pediatric patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mefenamic acid + paracetamol (Rax Health Care).